Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;95(3):692-697.
doi: 10.1038/s41390-023-02519-z. Epub 2023 Feb 16.

Intravenous immunoglobulin resistance in Kawasaki disease patients: prediction using clinical data

Affiliations

Intravenous immunoglobulin resistance in Kawasaki disease patients: prediction using clinical data

Jonathan Y Lam et al. Pediatr Res. 2024 Feb.

Abstract

Background: About 10-20% of Kawasaki disease (KD) patients are resistant to the initial infusion of intravenous immunoglobin (IVIG). The aim of this study was to assess whether IVIG resistance in KD patients could be predicted using standard clinical and laboratory features.

Methods: Data were from two cohorts: a Korean cohort of 7101 KD patients from 2015 to 2017 and a cohort of 649 KD patients from San Diego enrolled from 1998 to 2021. Features included laboratory values, the worst Z-score from the initial echocardiogram or during hospitalization, and the five clinical KD signs at presentation.

Results: Five machine learning models achieved a maximum median AUC of 0.711 [IQR: 0.706-0.72] in the Korean cohort and 0.696 [IQR: 0.609-0.722] in the San Diego cohort during stratified 10-fold cross-validation using significant laboratory features identified from univariate analysis. Adding the Z-score, KD clinical signs, or both did not considerably improve the median AUC in either cohort.

Conclusions: Using commonly measured clinical laboratory data alone or in conjunction with echocardiographic findings and clinical features is not sufficient to predict IVIG resistance. Further attempts to predict IVIG resistance will need to incorporate additional data such as transcriptomics, proteomics, and genetics to achieve meaningful predictive utility.

Impact: We demonstrated that laboratory, echocardiographic, and clinical findings cannot predict intravenous immunoglobin (IVIG) resistance to a clinically meaningful extent using machine learning in a homogenous Asian or ethnically diverse population of patients with Kawasaki disease (KD). Visualizing these features using uniform manifold approximation and projection (UMAP) is an important step to evaluate predictive utility in a qualitative manner. Further attempts to predict IVIG resistance in KD patients will need to incorporate novel biomarkers or other specialized features such as genetic differences or transcriptomics to be clinically useful.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. UMAP embeddings of KD patients for the Korean and San Diego cohorts labeled by IVIG resistance.
a Normalized significant laboratory features only, b normalized significant laboratory features and echocardiographic findings (worst Z-score), c normalized significant laboratory features and significant classical KD signs, and d normalized significant laboratory features, echocardiographic findings (worst Z-score), and significant classical KD signs.
Fig. 2
Fig. 2. Performance of models trained on feature sets defined through recursive feature elimination.
a Median AUC from the Korean cohort, b median AUC from the San Diego cohort, c sensitivity from the Korean cohort, and d sensitivity from the San Diego cohort. LR logistic regression, RF random forest, GBM gradient boosting machine, NN neural network.

Similar articles

Cited by

References

    1. McCrindle BW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e999. doi: 10.1161/CIR.0000000000000484. - DOI - PubMed
    1. Tremoulet AH, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J. Pediatr. 2008;153:117–121.e3. doi: 10.1016/j.jpeds.2007.12.021. - DOI - PMC - PubMed
    1. Bar-Meir, M. et al. Prediction of resistance to intravenous immunoglobulin in children with Kawasaki disease. J. Pediatr. Infect. Dis. Soc. 10.1093/jpids/piw075 (2017). - PubMed
    1. Phuong LK, Curtis N, Gowdie P, Akikusa J, Burgner D. Treatment options for resistant Kawasaki disease. Pediatr. Drugs. 2018;20:59–80. doi: 10.1007/s40272-017-0269-6. - DOI - PubMed
    1. Kobayashi T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606–2612. doi: 10.1161/CIRCULATIONAHA.105.592865. - DOI - PubMed